Eradavir — Influenza Treatment RCT

[Scientific Research] Open Philanthropy recommended an investment of $250,000 in Eradavir to support a randomized controlled trial of a drug for treating influenza. The team’s novel antiviral approach links two haptens that recruit the immune system to an already approved influenza antiviral, zanamivir, which binds to the neuraminidase protein found on the virus and infected cell. This follows our July 2023 investment and falls within our focus area of scientific research.